Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Efanesoctocog alfa -ennaltaehkäisy potilailla, joilla on hemofilia A nivel -hypertrofia, (SYNOVIIIUS)

perjantai 6. marraskuuta 2026 päivittänyt: Sanofi

Prospektiivinen interventio Efanesoctocog ALFA: n ennaltaehkäisyn tehokkuudesta nivelten hypertrofiaan potilailla, joilla on hemofilia A

The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week (QW) in joints with existing evidence of synovial hypertrophy in participants with hemophilia A.

The study duration for each participant is approximately 12 months.

Tutkimuksen yleiskatsaus

Tila

Rekrytointi

Interventio / Hoito

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

35

Vaihe

  • Vaihe 4

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

  • Nimi: Trial Transparency email recommended (Toll free for US & Canada)
  • Puhelinnumero: option 6 800-633-1610
  • Sähköposti: Contact-US@sanofi.com

Opiskelupaikat

    • Western Australia
      • Murdoch, Western Australia, Australia, 6150
        • Valmis
        • Investigational Site Number : 0360001
      • Hiroshima, Japani, 734-8551
        • Valmis
        • Investigational Site Number : 3920002
      • Saitama, Japani, 330-8777
        • Rekrytointi
        • Investigational Site Number : 3920001
      • Tokyo, Japani, 160-0023
        • Valmis
        • Investigational Site Number : 3920004
    • Kanagawa
      • Kawasaki, Kanagawa, Japani, 216-8511
        • Rekrytointi
        • Investigational Site Number : 3920003
    • Alberta
      • Calgary, Alberta, Kanada, T2N 1N4
        • Rekrytointi
        • Investigational Site Number : 1240002
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Kanada, A1B 3V6
        • Rekrytointi
        • Investigational Site Number : 1240001
    • Ontario
      • Hamilton, Ontario, Kanada, L8N 3Z5
        • Rekrytointi
        • Investigational Site Number : 1240003
      • Hamilton, Ontario, Kanada, L8N 3Z5
        • Valmis
        • Investigational Site Number : 1240004
      • Kaohsiung City, Taiwan, 80756
        • Rekrytointi
        • Investigational Site Number: 1580003
      • Taichung, Taiwan, 407
        • Rekrytointi
        • Investigational Site Number: 1580001
      • Taipei, Taiwan, 114
        • Rekrytointi
        • Investigational Site Number: 1580002
    • California
      • Los Angeles, California, Yhdysvallat, 90007
        • Valmis
        • Orthopedic Institute for Children- Site Number : 8400009
      • Sacramento, California, Yhdysvallat, 95817-1399
        • Rekrytointi
        • University of California Davis Medical Center-Site Number: 8400005
    • Indiana
      • Indianapolis, Indiana, Yhdysvallat, 46260
        • Rekrytointi
        • Indiana Hemophilia and Thrombosis Center- Site Number : 8400006
    • Iowa
      • Iowa City, Iowa, Yhdysvallat, 52242
        • Rekrytointi
        • University of Iowa- Site Number : 8400004
    • Ohio
      • Columbus, Ohio, Yhdysvallat, 43203
        • Valmis
        • The Ohio State University Wexner Medical Center - CarePoint East- Site Number : 8400001
    • Oregon
      • Portland, Oregon, Yhdysvallat, 97239-3011
        • Rekrytointi
        • Oregon Health and Science University-Site Number: 8400002
    • Washington
      • Seattle, Washington, Yhdysvallat, 98101-3932
        • Rekrytointi
        • Washington Center for Bleeding Disorders- Site Number : 8400008

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

12 vuotta ja vanhemmat (Lapsi, Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Participant is diagnosed with moderate to severe hemophilia A (defined as less than or equal to (≤)5 percent (%) of endogenous FVIII clotting activity) at the time of consent/assent.

  • Participant is more than or equal to (≥)12 years old at the time of consent/assent.

  • Participant has existing synovial hypertrophy, defined as at least 1 eligible* joint by the HEAD-US score (Synovitis score: 1 or 2) at the time of consent/assent.

  • Participant has at least 1 eligible* joint without planned future major orthopedic procedures (example, arthroscopic synovectomy, radioisotopic or chemical synoviorthesis), or major orthopedic procedures in the past 3 months prior to the screening visit (Visit 1).

    *An eligible joint is a joint with existing synovial hypertrophy, as defined by a HEAD-US synovitis score of 1 or 2, considering hypertrophic synovium as an indication of the presence of synovitis

  • Participant has received prophylactic treatment with hemophilia prophylaxis prescriptions in the last 12 months prior to the baseline visit (Visit 2).

  • Participant is capable of understanding the written Informed Consent Form (ICF)/assent form, provides a signed and witnessed written ICF/assent form, and agrees to comply with the protocol requirements.

  • If male, no contraceptive measures are required for this study.

  • If female, is not pregnant or breastfeeding, and one of the following conditions applies:

  • Is a women of nonchildbearing potential (WONCBP)

  • Is a WOCBP and agrees to use a highly effective contraceptive method, with a failure rate of less than (<)1 percent during the study treatment period (at least until the Week 52/ End of Treatment [EoT] visit).

  • A WOCBP must have a negative serum pregnancy test at the screening visit (Visit 1)

Exclusion Criteria:

  • Participants are excluded from the study if any of the following criteria apply:
  • Has other associated clotting disorders at the time of consent/assent.
  • Is already under efanesoctocog alfa treatment.
  • Has a current diagnosis of an factor VIII (FVIII) inhibitor, defined as inhibitor titer ≥0.60 BU/mL.
  • Has ITI within the last 2 years prior to the baseline visit (Visit 2).
  • Has been enrolled in a concurrent clinical interventional study or exposed to other investigational drug(s) within 3 months prior to screening for this study.
  • Is currently in an institution because of regulatory or legal order (that is, is a prisoner or a patient who is legally institutionalized).
  • Is not suitable for participation, whatever the reason, as judged by the investigator, including medical or clinical conditions, or patients potentially at risk of noncompliance to study procedures.
  • Is an employee or family member of the investigator or site personnel.
  • Is involved in a specific situation during study implementation or the course of the study that may raise ethics considerations.
  • Has hypersensitivity to efanesoctocog alfa or its components or any of its excipients that, in the opinion of the investigator, contraindicates participation in the study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Ei satunnaistettu
  • Inventiomalli: Yksittäinen ryhmätehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Efanesoctocog Alfa

Participants will receive Efanesoctocog Alfa at 50 international unit per kilogram (IU/kg) intravenous (IV) QW

Pharmaceutical form:Lyophilized powder in a sterile vial that requires reconstitution with sterile water for injection (diluent)-Route of administration:Intravenous

Muut nimet:
  • BIVV001
  • Altuviiio®

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Proportion of joints with improvement in the Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) synovitis domain score
Aikaikkuna: From Baseline up to Week 52

HEAD-US scoring system is a simplified ultrasound scanning procedure to image the elbow, knee, and ankle (index joints) and a scoring system based on an additive scale to define the joint status from disease activity and disease damage parameters to evaluate disease progression and monitor the results of treatment.

From Baseline up to Week 52

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change from baseline in the distribution of joint HEAD-US synovitis score
Aikaikkuna: From Baseline up to Week 52

HEAD-US scoring system is a simplified ultrasound scanning procedure to image the elbow, knee, and ankle (index joints) and a scoring system based on an additive scale to define the joint status from disease activity and disease damage parameters to evaluate disease progression and monitor the results of treatment.

From Baseline up to Week 52
Number of joints with the HEAD-US synovitis domain score that has remained unchanged or worsened
Aikaikkuna: From Baseline up to Week 52

HEAD-US scoring system is a simplified ultrasound scanning procedure to image the elbow, knee, and ankle (index joints) and a scoring system based on an additive scale to define the joint status from disease activity and disease damage parameters to evaluate disease progression and monitor the results of treatment.

From Baseline up to Week 52
Percentage of joints with the HEAD-US synovitis domain score that has remained unchanged or worsened
Aikaikkuna: From Baseline up to Week 52

HEAD-US scoring system is a simplified ultrasound scanning procedure to image the elbow, knee, and ankle (index joints) and a scoring system based on an additive scale to define the joint status from disease activity and disease damage parameters to evaluate disease progression and monitor the results of treatment.

From Baseline up to Week 52
Number of index joint type with the HEAD-US synovitis domain score that has improved, remained unchanged, or worsened
Aikaikkuna: From Baseline up to Week 52

HEAD-US scoring system is a simplified ultrasound scanning procedure to image the elbow, knee, and ankle (index joints) and a scoring system based on an additive scale to define the joint status from disease activity and disease damage parameters to evaluate disease progression and monitor the results of treatment.

From Baseline up to Week 52
Percentage of index joint type with the HEAD-US synovitis domain score that has improved, remained unchanged, or worsened
Aikaikkuna: From Baseline up to Week 52

HEAD-US scoring system is a simplified ultrasound scanning procedure to image the elbow, knee, and ankle (index joints) and a scoring system based on an additive scale to define the joint status from disease activity and disease damage parameters to evaluate disease progression and monitor the results of treatment.

From Baseline up to Week 52
Number of participants with at least 1 joint with the HEAD-US synovitis domain score that has improved, remained unchanged, or worsened
Aikaikkuna: From Baseline up to Week 52

HEAD-US scoring system is a simplified ultrasound scanning procedure to image the elbow, knee, and ankle (index joints) and a scoring system based on an additive scale to define the joint status from disease activity and disease damage parameters to evaluate disease progression and monitor the results of treatment.

From Baseline up to Week 52
Percentage of participants with at least 1 joint with the HEAD-US synovitis domain score that has improved, remained unchanged, or worsened
Aikaikkuna: From Baseline up to Week 52

HEAD-US scoring system is a simplified ultrasound scanning procedure to image the elbow, knee, and ankle (index joints) and a scoring system based on an additive scale to define the joint status from disease activity and disease damage parameters to evaluate disease progression and monitor the results of treatment.

From Baseline up to Week 52
Change from baseline in average HEAD-US synovitis domain score across all index joints
Aikaikkuna: From Baseline up to Week 52

HEAD-US scoring system is a simplified ultrasound scanning procedure to image the elbow, knee, and ankle (index joints) and a scoring system based on an additive scale to define the joint status from disease activity and disease damage parameters to evaluate disease progression and monitor the results of treatment.

From Baseline up to Week 52
Change from baseline in total/ domain scores of the HEAD-US
Aikaikkuna: From Baseline up to Week 26

HEAD-US scoring system is a simplified ultrasound scanning procedure to image the elbow, knee, and ankle (index joints) and a scoring system based on an additive scale to define the joint status from disease activity and disease damage parameters to evaluate disease progression and monitor the results of treatment.

From Baseline up to Week 26
Change from baseline in total/domain scores of the HJHS
Aikaikkuna: From Baseline up to Week 26

HJHS comprises an assessment of specific features, or items, of the 6 index joints and an assessment of global gait. For each of the 6 joints, the following items are scored: swelling (0 to 3), duration of swelling (0 to 1), muscle atrophy (0 to 2), crepitus on motion (0 to 2), flexion loss (0 to 3), extension loss (0 to 3), joint pain (0 to 2), and strength (0 to 4). The maximum score for an individual index joint is 20. Gait is scored from 0 to 4. The maximum HJHS total score is 124, with a higher score indicating worse joint health.

From Baseline up to Week 26
Change from baseline in total/domain scores of the HJHS
Aikaikkuna: From Baseline up to Week 52

HJHS comprises an assessment of specific features, or items, of the 6 index joints and an assessment of global gait. For each of the 6 joints, the following items are scored: swelling (0 to 3), duration of swelling (0 to 1), muscle atrophy (0 to 2), crepitus on motion (0 to 2), flexion loss (0 to 3), extension loss (0 to 3), joint pain (0 to 2), and strength (0 to 4). The maximum score for an individual index joint is 20. Gait is scored from 0 to 4. The maximum HJHS total score is 124, with a higher score indicating worse joint health.

From Baseline up to Week 52
Change from baseline in total/ domain scores of magnetic resonance imaging (MRI)
Aikaikkuna: From Baseline up to Week 52

MRI will be used to detect changes in synovial hypertrophy in index joints of participants.

From Baseline up to Week 52
Change from baseline in patient-reported outcome (PRO)
Aikaikkuna: From Baseline up to Week 52

Change from baseline in PRO will be assessed by the EQ-5D 5-level (EQ-5D-5L), Patient-Reported Outcomes Measurement Information System - Short Form (PROMIS-SF) version 2.0 Pain Intensity 3a, PROMIS-SF version 1.1 Pain Interference 6a, and PROMIS-SF version 2.0 Physical Function 6b.

From Baseline up to Week 52
Patient reported treatment preference and satisfaction
Aikaikkuna: At Week 52

Patient reported treatment preference and satisfaction will be assessed through surveys and exit interviews.

At Week 52
Change from baseline in annualized bleeding rate (ABR) (spontaneous, traumatic)
Aikaikkuna: At Week 52

The ABR will be defined as (number of bleeding episodes occurring during the treatment period)/(duration of the treatment period [days]) × 365.25.

At Week 52
Change from baseline in annualized joint bleeding rate (AjBR) (spontaneous, traumatic)
Aikaikkuna: At Week 52

The AjBR will be defined as (number of joint bleeding episodes occurring during the treatment period)/(duration of the treatment period [days]) × 365.25.

At Week 52
Change from baseline in target joint resolution, recurrence, or development
Aikaikkuna: At Week 52

Change from baseline in target joint resolution, recurrence, or development will be assessed.

At Week 52
The occurrence of Adverse Events (AEs), all AEs leading to treatment discontinuation, Serious Adverse Events (SAEs), and Adverse Event of Special Interest (AESIs)
Aikaikkuna: Up to Week 52

The safety and tolerability of efanesoctocog alfa evaluated in all participants

Up to Week 52

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Tiistai 23. syyskuuta 2025

Ensisijainen valmistuminen (Arvioitu)

Maanantai 25. lokakuuta 2027

Opintojen valmistuminen (Arvioitu)

Maanantai 25. lokakuuta 2027

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Keskiviikko 16. huhtikuuta 2025

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Keskiviikko 16. huhtikuuta 2025

Ensimmäinen Lähetetty (Todellinen)

Torstai 24. huhtikuuta 2025

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Maanantai 9. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Perjantai 6. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa